Cantor Starts Helicos BioSciences (HLCS) at Buy; $14 PT
More News related to HLCS
- Helicos BioSciences Announces Collaboration with Children's Oncology Group to Elucidate Genomic Signatures in Ewing's Sarcoma
- Helicos BioSciences to Present at the Bank of America 2008 Health Care Conference Tuesday, May 13, 2008
- Helicos BioSciences (HLCS) Announces Research Collaboration with City of Hope
- Cantor Starts Helicos BioSciences (HLCS) at Buy; $14 PT
- UBS Upgrades Helicos BioSciences (HLCS) to Neutral
More News related to New Coverage
- Governor Rendell to Sign Budget
- Media Advisory/Natural Resources Canada: Minister Lunn Highlights Critical Importance of Natural Resources to Rural Communities
- TSX Venture Exchange Daily Bulletins for July 4, 2008
- Baja Mining Releases Video Presentation on Financing Completion
- Baja Mining Releases Video Presentation on Financing Completion
Cantor Fitzgerald initiates coverage on Helicos BioSciences Corp. (Nasdaq: HLCS) with a Buy rating and $14 price target.
The firm calls Helicos the likely market segment leader in the genome sequencing space due breakthroughs using the HeliScope system. Cantor believes "the HeliScope provides a quality and cost advantage that is unmatched in the current market" as the product is the first integrated, comprehensive system in this market.
Cantor notes that Helicos just shipped its first HeliScope unit during Q108 and the firm expects additional system installations to make the Company profitable by 2010.
Helicos BioSciences Corporation, a life sciences company, engages in the development of genetic analysis technologies for the research, drug discovery, and clinical diagnostics markets. [BCS]
Related Categories
New CoverageStocks Mentioned
-0.66Related Entities
Sign up for StreetInsider Free!
Recieve full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
